A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors-Reference-Cited by-同舟云学术

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Published:2014-09-30 Issue:18 Volume:5 Page:8136-8146
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Soliman Hatem H.¹,Jackson Erica²,Neuger Tony¹,Dees E. Claire³,Harvey R. Donald⁴,Han Hyo¹,Ismail-Khan Roohi¹,Minton Susan¹,Vahanian Nicholas N.⁵,Link Charles⁵,Sullivan Daniel M.¹,Antonia Scott¹

Affiliation:

1. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

2. University of South Florida, Tampa, FL

3. University of North Carolina/Lineberger Cancer Center, Chapel Hill, NC

4. Winship Cancer Institute of Emory University, Atlanta, GA

5. NewLink Genetics Inc, Ames, IA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies;International Journal of Nanomedicine;2024-08

2. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression;International Immunopharmacology;2024-08

3. Metabolic Modulation of Kynurenine Based on Kynureninase-Loaded Nanoparticle Depot Overcomes Tumor Immune Evasion in Cancer Immunotherapy;ACS Applied Materials & Interfaces;2024-04-04

4. MGP+ and IDO1+ tumor-associated macrophages facilitate immunoresistance in breast cancer revealed by single-cell RNA sequencing;International Immunopharmacology;2024-04

5. Comprehensive analysis of the prognostic value and immunological role of IDO1 gene in pan-cancer;European Journal of Medical Research;2024-03-27